Israeli firm Dune Medical Devices has begun a U.S. clinical trial of its MarginProbe intraoperative breast cancer probe.
The U.S. Food and Drug Administration (FDA) recently granted the Caesarea-based company an investigational device exemption for its breast cancer surgery protocol. MarginProbe uses radiofrequency spectroscopy to characterize breast tissue during surgery to determine the malignancy status of tumor margins.
The study will involve more than 600 women in more than a dozen medical centers in New York City; Baltimore; Washington, DC; Allentown, PA; and Los Angeles, Dune said.
Related Reading
Dune Medical device shows promise for re-excision surgeries, May 11, 2007
Copyright © 2008 AuntMinnie.com
